← Back to Clinical Trials
Recruiting NCT07001449

NCT07001449 Effectiveness of Communication-Focused Pain Neuroscience Education in Chronic Musculoskeletal Pain

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07001449
Status Recruiting
Phase
Sponsor University of Thessaly
Condition Chronic Musculoskeletal Pain
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2025-06-17
Primary Completion 2026-08-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Pain Neuroscience Education with Communication TrainingPain Neuroscience Education without Communication TrainingUsual Physiotherapy Treatment

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 90 participants in total. It began in 2025-06-17 with a primary completion date of 2026-08-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This randomized controlled trial aims to evaluate the effectiveness of the "Algo(S)Therapy" Pain Neuroscience Education (PNE) program in patients with chronic musculoskeletal pain. The study will assess whether the integration of communication skills training for physiotherapists enhances the outcomes of PNE. Participants will be randomly assigned to one of three groups: (1) PNE with communication-focused delivery, (2) PNE without communication emphasis, or (3) standard- usual physiotherapy care. The primary objective is to determine whether PNE combined with enhanced communication skills leads to greater improvements in pain, function, and psychosocial outcomes compared to the other interventions.

Eligibility Criteria

Inclusion Criteria: * Adults aged 18 to 65 years * Diagnosis of chronic musculoskeletal pain in the lumbar spine, cervical spine, shoulder, or knee * Pain duration longer than 3 months * Pain intensity ≥3/10 on the Numeric Pain Rating Scale (NPRS) * Pain present most days of the week * Able to understand and speak the Greek language Exclusion Criteria: * Acute pain in any body region * Neurological disorders or myopathies * Chronic pain of non-musculoskeletal origin * Active cancer diagnosis * History of trauma, fractures, or surgery in the past year * Pregnancy * Diagnosis of fibromyalgia * Cognitive impairments affecting communication or completion of questionnaires * Current use of corticosteroid medication * Participation in other treatment programs or alternative therapies during the study period * Concurrent enrollment in another clinical trial

Contact & Investigator

Central Contact

Konstantina Savvoulidou

✉ ksavvoulidou@uth.gr

📞 +30 22310 6017

Principal Investigator

Eleni Kapreli, Professor

STUDY CHAIR

Physiotherapy Department, University of Thessaly, Greece

Frequently Asked Questions

Who can join the NCT07001449 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Chronic Musculoskeletal Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07001449 currently recruiting?

Yes, NCT07001449 is actively recruiting participants. Contact the research team at ksavvoulidou@uth.gr for enrollment information.

Where is the NCT07001449 trial being conducted?

This trial is being conducted at Lamia, Greece.

Who is sponsoring the NCT07001449 clinical trial?

NCT07001449 is sponsored by University of Thessaly. The principal investigator is Eleni Kapreli, Professor at Physiotherapy Department, University of Thessaly, Greece. The trial plans to enroll 90 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology